Global Diabetic Neuropathic Pain Drug Market Research Report 2021

Publisher Name :
Date: 11-Jan-2021
No. of pages: 117
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- AZD-5213

- Clonidine Hydrochloride

- Duloxetine Hydrochloride DR

- E-52862

- Filgrastim

- GERPOOI

- GRC-17536

- Others

Segment by Application

- Clinic

- Hospital

- Others

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

By Company

- Astellas Pharma Inc.

- AstraZeneca Plc

- BioDelivery Sciences International, Inc.

- Boehringer Ingelheim GmbH

- Daiichi Sankyo Company, Limited

- Dong-A Socio Group

- Eli Lilly and Company

- Glenmark Pharmaceuticals Ltd.

- Hydra Biosciences, Inc.

- Immune Pharmaceuticals Inc.

- Laboratorios Del Dr. Esteve S.A.

- Lohocla Research Corporation

- Mertiva AB

- Novaremed

- Pharmaleads

- RAPID Pharmaceuticals AG

- Relmada Therapeutics, Inc.

- Sphaera Pharma Pvt. Ltd.

- Theravasc, Inc.

Global Diabetic Neuropathic Pain Drug Market Research Report 2021

Table of Contents
1 Diabetic Neuropathic Pain Drug Market Overview
1.1 Product Overview and Scope of Diabetic Neuropathic Pain Drug
1.2 Diabetic Neuropathic Pain Drug Segment by Type
1.2.1 Global Diabetic Neuropathic Pain Drug Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 AZD-5213
1.2.3 Clonidine Hydrochloride
1.2.4 Duloxetine Hydrochloride DR
1.2.5 E-52862
1.2.6 Filgrastim
1.2.7 GERPOOI
1.2.8 GRC-17536
1.2.9 Others
1.3 Diabetic Neuropathic Pain Drug Segment by Application
1.3.1 Diabetic Neuropathic Pain Drug Sales Comparison by Application: (2021-2027)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Diabetic Neuropathic Pain Drug Market Size Estimates and Forecasts
1.4.1 Global Diabetic Neuropathic Pain Drug Revenue 2016-2027
1.4.2 Global Diabetic Neuropathic Pain Drug Sales 2016-2027
1.4.3 Diabetic Neuropathic Pain Drug Market Size by Region: 2016 Versus 2021 Versus 2027
2 Diabetic Neuropathic Pain Drug Market Competition by Manufacturers
2.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2016-2021)
2.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Diabetic Neuropathic Pain Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Diabetic Neuropathic Pain Drug Manufacturing Sites, Area Served, Product Type
2.5 Diabetic Neuropathic Pain Drug Market Competitive Situation and Trends
2.5.1 Diabetic Neuropathic Pain Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Diabetic Neuropathic Pain Drug Players Market Share by Revenue
2.5.3 Global Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Diabetic Neuropathic Pain Drug Retrospective Market Scenario by Region
3.1 Global Diabetic Neuropathic Pain Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Diabetic Neuropathic Pain Drug Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.3.1 North America Diabetic Neuropathic Pain Drug Sales by Country
3.3.2 North America Diabetic Neuropathic Pain Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.4.1 Europe Diabetic Neuropathic Pain Drug Sales by Country
3.4.2 Europe Diabetic Neuropathic Pain Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Diabetic Neuropathic Pain Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region
3.5.2 Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.6.1 Latin America Diabetic Neuropathic Pain Drug Sales by Country
3.6.2 Latin America Diabetic Neuropathic Pain Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country
3.7.2 Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Diabetic Neuropathic Pain Drug Historic Market Analysis by Type
4.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2016-2021)
4.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2016-2021)
4.3 Global Diabetic Neuropathic Pain Drug Price by Type (2016-2021)
5 Global Diabetic Neuropathic Pain Drug Historic Market Analysis by Application
5.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2016-2021)
5.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2016-2021)
5.3 Global Diabetic Neuropathic Pain Drug Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Astellas Pharma Inc.
6.1.1 Astellas Pharma Inc. Corporation Information
6.1.2 Astellas Pharma Inc. Description and Business Overview
6.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Astellas Pharma Inc. Product Portfolio
6.1.5 Astellas Pharma Inc. Recent Developments/Updates
6.2 AstraZeneca Plc
6.2.1 AstraZeneca Plc Corporation Information
6.2.2 AstraZeneca Plc Description and Business Overview
6.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.2.4 AstraZeneca Plc Product Portfolio
6.2.5 AstraZeneca Plc Recent Developments/Updates
6.3 BioDelivery Sciences International, Inc.
6.3.1 BioDelivery Sciences International, Inc. Corporation Information
6.3.2 BioDelivery Sciences International, Inc. Description and Business Overview
6.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.3.4 BioDelivery Sciences International, Inc. Product Portfolio
6.3.5 BioDelivery Sciences International, Inc. Recent Developments/Updates
6.4 Boehringer Ingelheim GmbH
6.4.1 Boehringer Ingelheim GmbH Corporation Information
6.4.2 Boehringer Ingelheim GmbH Description and Business Overview
6.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Boehringer Ingelheim GmbH Product Portfolio
6.4.5 Boehringer Ingelheim GmbH Recent Developments/Updates
6.5 Daiichi Sankyo Company, Limited
6.5.1 Daiichi Sankyo Company, Limited Corporation Information
6.5.2 Daiichi Sankyo Company, Limited Description and Business Overview
6.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Daiichi Sankyo Company, Limited Product Portfolio
6.5.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
6.6 Dong-A Socio Group
6.6.1 Dong-A Socio Group Corporation Information
6.6.2 Dong-A Socio Group Description and Business Overview
6.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Dong-A Socio Group Product Portfolio
6.6.5 Dong-A Socio Group Recent Developments/Updates
6.7 Eli Lilly and Company
6.6.1 Eli Lilly and Company Corporation Information
6.6.2 Eli Lilly and Company Description and Business Overview
6.6.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Eli Lilly and Company Product Portfolio
6.7.5 Eli Lilly and Company Recent Developments/Updates
6.8 Glenmark Pharmaceuticals Ltd.
6.8.1 Glenmark Pharmaceuticals Ltd. Corporation Information
6.8.2 Glenmark Pharmaceuticals Ltd. Description and Business Overview
6.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Glenmark Pharmaceuticals Ltd. Product Portfolio
6.8.5 Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
6.9 Hydra Biosciences, Inc.
6.9.1 Hydra Biosciences, Inc. Corporation Information
6.9.2 Hydra Biosciences, Inc. Description and Business Overview
6.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Hydra Biosciences, Inc. Product Portfolio
6.9.5 Hydra Biosciences, Inc. Recent Developments/Updates
6.10 Immune Pharmaceuticals Inc.
6.10.1 Immune Pharmaceuticals Inc. Corporation Information
6.10.2 Immune Pharmaceuticals Inc. Description and Business Overview
6.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Immune Pharmaceuticals Inc. Product Portfolio
6.10.5 Immune Pharmaceuticals Inc. Recent Developments/Updates
6.11 Laboratorios Del Dr. Esteve S.A.
6.11.1 Laboratorios Del Dr. Esteve S.A. Corporation Information
6.11.2 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Description and Business Overview
6.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Laboratorios Del Dr. Esteve S.A. Product Portfolio
6.11.5 Laboratorios Del Dr. Esteve S.A. Recent Developments/Updates
6.12 Lohocla Research Corporation
6.12.1 Lohocla Research Corporation Corporation Information
6.12.2 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Description and Business Overview
6.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Lohocla Research Corporation Product Portfolio
6.12.5 Lohocla Research Corporation Recent Developments/Updates
6.13 Mertiva AB
6.13.1 Mertiva AB Corporation Information
6.13.2 Mertiva AB Diabetic Neuropathic Pain Drug Description and Business Overview
6.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Mertiva AB Product Portfolio
6.13.5 Mertiva AB Recent Developments/Updates
6.14 Novaremed
6.14.1 Novaremed Corporation Information
6.14.2 Novaremed Diabetic Neuropathic Pain Drug Description and Business Overview
6.14.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Novaremed Product Portfolio
6.14.5 Novaremed Recent Developments/Updates
6.15 Pharmaleads
6.15.1 Pharmaleads Corporation Information
6.15.2 Pharmaleads Diabetic Neuropathic Pain Drug Description and Business Overview
6.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Pharmaleads Product Portfolio
6.15.5 Pharmaleads Recent Developments/Updates
6.16 RAPID Pharmaceuticals AG
6.16.1 RAPID Pharmaceuticals AG Corporation Information
6.16.2 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Description and Business Overview
6.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.16.4 RAPID Pharmaceuticals AG Product Portfolio
6.16.5 RAPID Pharmaceuticals AG Recent Developments/Updates
6.17 Relmada Therapeutics, Inc.
6.17.1 Relmada Therapeutics, Inc. Corporation Information
6.17.2 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Description and Business Overview
6.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Relmada Therapeutics, Inc. Product Portfolio
6.17.5 Relmada Therapeutics, Inc. Recent Developments/Updates
6.18 Sphaera Pharma Pvt. Ltd.
6.18.1 Sphaera Pharma Pvt. Ltd. Corporation Information
6.18.2 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Description and Business Overview
6.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Sphaera Pharma Pvt. Ltd. Product Portfolio
6.18.5 Sphaera Pharma Pvt. Ltd. Recent Developments/Updates
6.19 Theravasc, Inc.
6.19.1 Theravasc, Inc. Corporation Information
6.19.2 Theravasc, Inc. Diabetic Neuropathic Pain Drug Description and Business Overview
6.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.19.4 Theravasc, Inc. Product Portfolio
6.19.5 Theravasc, Inc. Recent Developments/Updates
7 Diabetic Neuropathic Pain Drug Manufacturing Cost Analysis
7.1 Diabetic Neuropathic Pain Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
7.4 Diabetic Neuropathic Pain Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Diabetic Neuropathic Pain Drug Distributors List
8.3 Diabetic Neuropathic Pain Drug Customers
9 Diabetic Neuropathic Pain Drug Market Dynamics
9.1 Diabetic Neuropathic Pain Drug Industry Trends
9.2 Diabetic Neuropathic Pain Drug Growth Drivers
9.3 Diabetic Neuropathic Pain Drug Market Challenges
9.4 Diabetic Neuropathic Pain Drug Market Restraints
10 Global Market Forecast
10.1 Diabetic Neuropathic Pain Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Diabetic Neuropathic Pain Drug by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Diabetic Neuropathic Pain Drug by Type (2022-2027)
10.2 Diabetic Neuropathic Pain Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Diabetic Neuropathic Pain Drug by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Diabetic Neuropathic Pain Drug by Application (2022-2027)
10.3 Diabetic Neuropathic Pain Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Diabetic Neuropathic Pain Drug by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Diabetic Neuropathic Pain Drug by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) Comparison by Application (2021-2027)
Table 3. Global Diabetic Neuropathic Pain Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Diabetic Neuropathic Pain Drug Covered in This Study
Table 5. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) of Key Manufacturers (2016-2021)
Table 6. Global Diabetic Neuropathic Pain Drug Sales Share by Manufacturers (2016-2021)
Table 7. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Diabetic Neuropathic Pain Drug Average Price (USD/Pcs) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Diabetic Neuropathic Pain Drug Manufacturing Sites and Area Served
Table 11. Manufacturers Diabetic Neuropathic Pain Drug Product Type
Table 12. Global Diabetic Neuropathic Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Diabetic Neuropathic Pain Drug Sales by Region (2016-2021) & (K Pcs)
Table 16. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2016-2021)
Table 17. Global Diabetic Neuropathic Pain Drug Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Diabetic Neuropathic Pain Drug Sales by Country (2016-2021) & (K Pcs)
Table 19. North America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2016-2021)
Table 20. North America Diabetic Neuropathic Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2016-2021)
Table 22. Europe Diabetic Neuropathic Pain Drug Sales by Country (2016-2021) & (K Pcs)
Table 23. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country (2016-2021)
Table 24. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2016-2021) & (K Pcs)
Table 27. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2016-2021)
Table 30. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2016-2021) & (K Pcs)
Table 31. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2016-2021)
Table 32. Latin America Diabetic Neuropathic Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2016-2021) & (K Pcs)
Table 35. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2016-2021)
Table 38. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2016-2021)
Table 39. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2016-2021)
Table 40. Global Diabetic Neuropathic Pain Drug Revenue (Million US$) by Type (2016-2021)
Table 41. Global Diabetic Neuropathic Pain Drug Revenue Share by Type (2016-2021)
Table 42. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Type (2016-2021)
Table 43. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2016-2021)
Table 44. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2016-2021)
Table 45. Global Diabetic Neuropathic Pain Drug Revenue (Million US$) by Application (2016-2021)
Table 46. Global Diabetic Neuropathic Pain Drug Revenue Share by Application (2016-2021)
Table 47. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Application (2016-2021)
Table 48. Astellas Pharma Inc. Corporation Information
Table 49. Astellas Pharma Inc. Description and Business Overview
Table 50. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 51. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product
Table 52. Astellas Pharma Inc. Recent Developments/Updates
Table 53. AstraZeneca Plc Corporation Information
Table 54. AstraZeneca Plc Description and Business Overview
Table 55. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 56. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product
Table 57. AstraZeneca Plc Recent Developments/Updates
Table 58. BioDelivery Sciences International, Inc. Corporation Information
Table 59. BioDelivery Sciences International, Inc. Description and Business Overview
Table 60. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 61. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product
Table 62. BioDelivery Sciences International, Inc. Recent Developments/Updates
Table 63. Boehringer Ingelheim GmbH Corporation Information
Table 64. Boehringer Ingelheim GmbH Description and Business Overview
Table 65. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 66. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product
Table 67. Boehringer Ingelheim GmbH Recent Developments/Updates
Table 68. Daiichi Sankyo Company, Limited Corporation Information
Table 69. Daiichi Sankyo Company, Limited Description and Business Overview
Table 70. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 71. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product
Table 72. Daiichi Sankyo Company, Limited Recent Developments/Updates
Table 73. Dong-A Socio Group Corporation Information
Table 74. Dong-A Socio Group Description and Business Overview
Table 75. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 76. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product
Table 77. Dong-A Socio Group Recent Developments/Updates
Table 78. Eli Lilly and Company Corporation Information
Table 79. Eli Lilly and Company Description and Business Overview
Table 80. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 81. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product
Table 82. Eli Lilly and Company Recent Developments/Updates
Table 83. Glenmark Pharmaceuticals Ltd. Corporation Information
Table 84. Glenmark Pharmaceuticals Ltd. Description and Business Overview
Table 85. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 86. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product
Table 87. Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
Table 88. Hydra Biosciences, Inc. Corporation Information
Table 89. Hydra Biosciences, Inc. Description and Business Overview
Table 90. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 91. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product
Table 92. Hydra Biosciences, Inc. Recent Developments/Updates
Table 93. Immune Pharmaceuticals Inc. Corporation Information
Table 94. Immune Pharmaceuticals Inc. Description and Business Overview
Table 95. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 96. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product
Table 97. Immune Pharmaceuticals Inc. Recent Developments/Updates
Table 98. Laboratorios Del Dr. Esteve S.A. Corporation Information
Table 99. Laboratorios Del Dr. Esteve S.A. Description and Business Overview
Table 100. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 101. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product
Table 102. Laboratorios Del Dr. Esteve S.A. Recent Developments/Updates
Table 103. Lohocla Research Corporation Corporation Information
Table 104. Lohocla Research Corporation Description and Business Overview
Table 105. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 106. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product
Table 107. Lohocla Research Corporation Recent Developments/Updates
Table 108. Mertiva AB Corporation Information
Table 109. Mertiva AB Description and Business Overview
Table 110. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 111. Mertiva AB Diabetic Neuropathic Pain Drug Product
Table 112. Mertiva AB Recent Developments/Updates
Table 113. Novaremed Corporation Information
Table 114. Novaremed Description and Business Overview
Table 115. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 116. Novaremed Diabetic Neuropathic Pain Drug Product
Table 117. Novaremed Recent Developments/Updates
Table 118. Pharmaleads Corporation Information
Table 119. Pharmaleads Description and Business Overview
Table 120. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 121. Pharmaleads Diabetic Neuropathic Pain Drug Product
Table 122. Pharmaleads Recent Developments/Updates
Table 123. RAPID Pharmaceuticals AG Corporation Information
Table 124. RAPID Pharmaceuticals AG Description and Business Overview
Table 125. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 126. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product
Table 127. RAPID Pharmaceuticals AG Recent Developments/Updates
Table 128. Relmada Therapeutics, Inc. Corporation Information
Table 129. Relmada Therapeutics, Inc. Description and Business Overview
Table 130. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 131. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product
Table 132. Relmada Therapeutics, Inc. Recent Developments/Updates
Table 133. Sphaera Pharma Pvt. Ltd. Corporation Information
Table 134. Sphaera Pharma Pvt. Ltd. Description and Business Overview
Table 135. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 136. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product
Table 137. Sphaera Pharma Pvt. Ltd. Recent Developments/Updates
Table 138. Theravasc, Inc. Corporation Information
Table 139. Theravasc, Inc. Description and Business Overview
Table 140. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 141. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product
Table 142. Theravasc, Inc. Recent Developments/Updates
Table 143. Production Base and Market Concentration Rate of Raw Material
Table 144. Key Suppliers of Raw Materials
Table 145. Diabetic Neuropathic Pain Drug Distributors List
Table 146. Diabetic Neuropathic Pain Drug Customers List
Table 147. Diabetic Neuropathic Pain Drug Market Trends
Table 148. Diabetic Neuropathic Pain Drug Growth Drivers
Table 149. Diabetic Neuropathic Pain Drug Market Restraints
Table 150. Global Diabetic Neuropathic Pain Drug Sales Forecast by Type (2022-2027) & (K Pcs)
Table 151. Global Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Type (2022-2027)
Table 152. Global Diabetic Neuropathic Pain Drug Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 153. Global Diabetic Neuropathic Pain Drug Revenue Market Share Forecast by Type (2022-2027)
Table 154. Global Diabetic Neuropathic Pain Drug Sales Forecast by Application (2022-2027) & (K Pcs)
Table 155. Global Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Application (2022-2027)
Table 156. Global Diabetic Neuropathic Pain Drug Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 157. Global Diabetic Neuropathic Pain Drug Revenue Market Share Forecast by Application (2022-2027)
Table 158. Global Diabetic Neuropathic Pain Drug Sales Forecast by Region (2022-2027) & (K Pcs)
Table 159. Global Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Region (2022-2027)
Table 160. Global Diabetic Neuropathic Pain Drug Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 161. Global Diabetic Neuropathic Pain Drug Revenue Market Share Forecast by Region (2022-2027)
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Diabetic Neuropathic Pain Drug
Figure 2. Global Diabetic Neuropathic Pain Drug Market Share by Type in 2020 & 2027
Figure 3. AZD-5213 Product Picture
Figure 4. Clonidine Hydrochloride Product Picture
Figure 5. Duloxetine Hydrochloride DR Product Picture
Figure 6. E-52862 Product Picture
Figure 7. Filgrastim Product Picture
Figure 8. GERPOOI Product Picture
Figure 9. GRC-17536 Product Picture
Figure 10. Others Product Picture
Figure 11. Global Diabetic Neuropathic Pain Drug Market Share by Application in 2020 & 2027
Figure 12. Clinic
Figure 13. Hospital
Figure 14. Others
Figure 15. Global Diabetic Neuropathic Pain Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Diabetic Neuropathic Pain Drug Market Size 2016-2027 (US$ Million)
Figure 17. Global Diabetic Neuropathic Pain Drug Sales 2016-2027 (K Pcs)
Figure 18. Global Diabetic Neuropathic Pain Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 19. Diabetic Neuropathic Pain Drug Sales Share by Manufacturers in 2020
Figure 20. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers in 2020
Figure 21. The Global 5 and 10 Largest Diabetic Neuropathic Pain Drug Players: Market Share by Revenue in 2020
Figure 22. Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 23. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2016-2021)
Figure 24. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region in 2020
Figure 25. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2016-2021)
Figure 26. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region in 2020
Figure 27. U.S. Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Canada Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Germany Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. France Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. U.K. Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Italy Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Russia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. China Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Japan Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. South Korea Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. India Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Australia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Taiwan Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Indonesia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Thailand Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Malaysia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Philippines Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Vietnam Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Mexico Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Brazil Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Argentina Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Turkey Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Saudi Arabia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 50. U.A.E Diabetic Neuropathic Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. Sales Market Share of Diabetic Neuropathic Pain Drug by Type (2016-2021)
Figure 52. Sales Market Share of Diabetic Neuropathic Pain Drug by Application (2016-2021)
Figure 53. Sales Market Share of Diabetic Neuropathic Pain Drug by Application in 2020
Figure 54. Revenue
  • Global Transforming Growth Factor Beta 1 Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 134
    According to this latest study, the 2020 growth of Transforming Growth Factor Beta 1 will have significant change from previous year. By the most conservative estimates of global Transforming Growth Factor Beta 1 market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 1280.3 million in 2019. Over the next five years the Transforming Growth Factor Beta 1 market will register a 11.5% CAGR in terms of revenue, the global market size will reach US$ 198......
  • Global Traveler's Diarrhea Therapeutics Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 137
    According to this latest study, the 2020 growth of Traveler's Diarrhea Therapeutics will have significant change from previous year. By the most conservative estimates of global Traveler's Diarrhea Therapeutics market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 711.6 million in 2019. Over the next five years the Traveler's Diarrhea Therapeutics market will register a 7.4% CAGR in terms of revenue, the global market size will reach US$ 945.6 mi......
  • Global Anticoagulant Drugs Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 133
    According to this latest study, the 2020 growth of Anticoagulant Drugs will have significant change from previous year. By the most conservative estimates of global Anticoagulant Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 26520 million in 2019. Over the next five years the Anticoagulant Drugs market will register a 5.0% CAGR in terms of revenue, the global market size will reach US$ 32210 million by 2025. This repo......
  • Global OTC Herbal and Traditional Medicines Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 179
    According to this latest study, the 2020 growth of OTC Herbal and Traditional Medicines will have significant change from previous year. By the most conservative estimates of global OTC Herbal and Traditional Medicines market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 137320 million in 2019. Over the next five years the OTC Herbal and Traditional Medicines market will register a 2.8% CAGR in terms of revenue, the global market size will reach......
  • Global Levonorgestrel Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 138
    According to this latest study, the 2020 growth of Levonorgestrel will have significant change from previous year. By the most conservative estimates of global Levonorgestrel market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Levonorgestrel market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehe......
  • Global Cabazitaxel Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 138
    According to this latest study, the 2020 growth of Cabazitaxel will have significant change from previous year. By the most conservative estimates of global Cabazitaxel market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 189.2 million in 2019. Over the next five years the Cabazitaxel market will register a 5.5% CAGR in terms of revenue, the global market size will reach US$ 234.3 million by 2025. This report presents a comprehens......
  • Global Rydapt Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 135
    According to this latest study, the 2020 growth of Rydapt will have significant change from previous year. By the most conservative estimates of global Rydapt market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 213.2 million in 2019. Over the next five years the Rydapt market will register a 22.2% CAGR in terms of revenue, the global market size will reach US$ 475.4 million by 2025. This report presents a comprehensive overview, ......
  • Global Nausea And Vomiting Treatment Market Growth (Status and Outlook) 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 131
    According to this latest study, the 2020 growth of Nausea And Vomiting Treatment will have significant change from previous year. By the most conservative estimates of global Nausea And Vomiting Treatment market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 4518.9 million in 2019. Over the next five years the Nausea And Vomiting Treatment market will register a 6.7% CAGR in terms of revenue, the global market size will reach US$ 5866.6 million b......
  • Global Hydroxyprogesterone Caproate Injection Market Growth 2021-2026
    Published: 25-Jan-2021        Price: US 3660 Onwards        Pages: 135
    According to this latest study, the 2020 growth of Hydroxyprogesterone Caproate Injection will have significant change from previous year. By the most conservative estimates of global Hydroxyprogesterone Caproate Injection market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 249.7 million in 2019. Over the next five years the Hydroxyprogesterone Caproate Injection market will register a 1.6% CAGR in terms of revenue, the global market size will ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs